Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sichuan Huiyu Pharmaceutical CoSHSE:688553 +2.40%67 Return-on-Tangible-Equity is 2.40% as of Mar. 2026, which is 72% below its 10-year median of 8.58. GuruFocus rates SHSE:688553 with a GF Score™ of 67/100 and a GF Value™ of ¥9.82 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 901 Drug Manufacturers companies, Sichuan Huiyu Pharmaceutical Co ranks worse than 69.92% on this metric.
The historical rank and industry rank for Sichuan Huiyu Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688553'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -0.66 Med: 8.58 Max: 156.26
Current: 0.61
During the past 9 years, Sichuan Huiyu Pharmaceutical Co's highest Return-on-Tangible-Equity was 156.26%. The lowest was -0.66%. And the median was 8.58%.
SHSE:688553's Return-on-Tangible-Equity is ranked worse than 69.92% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs SHSE:688553: 0.61
Sichuan Huiyu Pharmaceutical Co (SHSE:688553) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sichuan Huiyu Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Sichuan Huiyu Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Huiyu Pharmaceutical Co Return-on-Tangible-Equity Chart
SHSE:688553 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Huiyu Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Huiyu Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sichuan Huiyu Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sichuan Huiyu Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.40% mean?
Sichuan Huiyu Pharmaceutical Co (SHSE:688553) has a Return-on-Tangible-Equity of 2.40% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sichuan Huiyu Pharmaceutical Co and its competitors. This is 72% below median its historical median of 8.58. According to the industry distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #630 out of 901 companies in the Drug Manufacturers industry, placing it in the top 69.9%.
Is Sichuan Huiyu Pharmaceutical Co's Return-on-Tangible-Equity too high?
Sichuan Huiyu Pharmaceutical Co's current Return-on-Tangible-Equity of 2.40% is 72% below median its 10-year median of 8.58. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. Sichuan Huiyu Pharmaceutical Co's value of 2.40% is 69.5% below this industry median. Based on the distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #630 out of 901 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sichuan Huiyu Pharmaceutical Co has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Huiyu Pharmaceutical Co's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #630 out of 901 companies for Return-on-Tangible-Equity. This places Sichuan Huiyu Pharmaceutical Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.87. Sichuan Huiyu Pharmaceutical Co's value of 2.40% is 69.5% below this benchmark. While the company's 10-year median is 8.58 vs. the industry median of 7.87, Sichuan Huiyu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Huiyu Pharmaceutical Co's current Return-on-Tangible-Equity of 2.40% is 69.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sichuan Huiyu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Huiyu Pharmaceutical Co's current Return-on-Tangible-Equity is 2.40%, which is 72% below median its own 10-year median of 8.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Huiyu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Huiyu Pharmaceutical Co (SHSE:688553) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥9.82, compared to a current price of ¥11.11 — trading 13.1% above its estimated fair value. The current Return-on-Tangible-Equity is 2.40%, which is 72% below median its 10-year median of 8.58 and 69.5% below the Drug Manufacturers industry median of 7.87. Sichuan Huiyu Pharmaceutical Co's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sichuan Huiyu Pharmaceutical Co (SHSE:688553), the current Return-on-Tangible-Equity is 2.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Huiyu Pharmaceutical Co (SHSE:688553) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Huiyu Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.11 is trading 13.1% above its estimated GF Value™ of ¥9.82.
GuruFocus considers Sichuan Huiyu Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:688553:
Return-on-Tangible-Equity: 2.40% (72% below median its 10-year median of 8.58)
GF Value™: ¥9.82 vs. price of ¥11.11 (13.1% above fair value)
Industry Position: 69.5% below the Drug Manufacturers median (#630 of 901)
No single metric tells the full story. See the SHSE:688553 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688553 has been successfully added to your 
